Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Energy Balance Pathways: Studying integrated metabolic response mechanisms
Here is a direct comparison from published Phase 2 and Phase 3 data: Semaglutide (Ozempic/Wegovy): Average weight loss of 14.9% at 68 weeks in the STEP 1 trial Tirzepatide (Mounjaro): Average weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial Retatrutide: Average weight loss of 24.2% at 48 weeks in the Phase 2 trial Retatrutide reached a higher percentage of weight loss in fewer weeks
Always verify current pricing, promotional terms, and subscription details directly on the official Elevate Health website before making your purchase
Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study
Making another peptide would not be a huge leap
US$ 20.74
US$ 29.54
US$ 20.74
US$ 26.85
US$ 22.95
US$ 29.35
